Is Devonian Health Group Inc. (DVHGF) a Buy, Sell, or Hold?
OTC : DVHGF
Devonian Health Group Inc. — News
$7 USD
$0 (0.0%)
- Volume
- 100
- Average Volume
- 61
- Market Capitalization
- $19.47M
- P/E Ratio
- -4.45
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $10.80
- Year Low
- $4.27
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.91
| Source | Headline |
|---|---|
|
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering PR Newswire gurufocus.com - 2026-07-27 21:00:00 |
|
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the NYSE American LLC (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of the Company's listing application and continued compliance with the exchange rules. prnewswire.com - 2026-07-27 20:00:00 |
|
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment. Secondary objectives include assessment of the overall safety and tolerability. prnewswire.com - 2026-07-21 08:45:00 |
|
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 PR Newswire gurufocus.com - 2026-06-29 21:00:00 |
|
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
(all amounts are in Canadian dollars) Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share Cash as of April 30, 2026, $0.7 million Company remains debt-free QUÉBEC, June 29, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlighted its financial and operating results for the three and nine months ended April 30, 2026. ''We are pleased with the continued momentum to execute on our priorities and readiness to advance our pipeline'', said Dr. André P. prnewswire.com - 2026-06-29 20:00:00 |
